Europe Frontotemporal Dementia Market to Witness Significant Growth until 2025

Increasing funding by government for R&D activities and rising life expectancy rate to drive Europe frontotemporal dementia market

According to TechSci Research report, “Europe Frontotemporal Dementia Market By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Country, Forecast & Opportunities, 2025”, the market is expected to undergo a formidable rate of growth during the forecast period owing to the focus of European nations towards providing best healthcare facilities to the population. Governments are also increasing funding for research and development activities to find the best treatment for neurological diseases such as frontotemporal dementia. Moreover, growing geriatric population, which is more prone to frontotemporal dementia, is also acting as a major factor behind the growth of this market in Europe. Moreover, the increasing life expectancy rate is expected to support the growth of Europe frontotemporal dementia market until 2025.

Additionally, various non-profit organizations are also providing financial aid and funding for drug development, which is acting as a major boost for the growth of this market. Extensive clinical trials to find the best treatment for frontotemporal dementia is further aiding the growth of the market. The availability of advanced care of treatments such as mental treatment centers and home care administrations in Europe is making the region a favorable market for the companies dealing in frontotemporal dementia.

However, the market also faces some major challenges. Lack of approved drugs and high chances of misunderstanding with Alzheimer’s disease might act as a restraint for the growth of Europe frontotemporal dementia market.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “Europe Frontotemporal Dementia Market”

https://www.techsciresearch.com/report/europe-frontotemporal-dementia-market/4859.html

The Europe frontotemporal dementia market is segmented based on drug class type, disease type, distribution channel, end user and region. Based on disease type, the Europe frontotemporal dementia market is categorized into Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA) and others. Among them, the Behavior Variant Frontotemporal Dementia segment is highly prevalent in Europe and  this is why the segment is expected to undergo rapid growth during the forecast period. Some common symptoms of behavior variant frontotemporal dementia include behavioral changes, apathy and changes in stereotypic behavior.

Based on drug class type, Europe frontotemporal dementia market is categorized into antidepressants and antipsychotics. Here, the antidepressant segment is poised to witness highest growth during the forecast period owing to their extensive use to minimize behavioral problems associated with frontotemporal dementia. Moreover, medical experts are also recommending antidepressants to manage the health of the patient which is acting as a major reason behind the growing demand for antidepressant drugs.

Major players operating in the Europe frontotemporal dementia market include GlaxoSmithKline PLC, Eli Lilly Italia – S.P.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Mylan Dura GmbH. Leading market players are also investing on clinical studies and trials for new drug developments.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4859

Customers can also request for 10% free customization on this report.

“According to the latest report by Dementia Statistics Organization, the number of people living with dementia is expected to increase to 152 million by 2025 around the world. The cases will certainly rise in Europe, which is witnessing surge in geriatric population. This is expected to propel the growth of frontotemporal dementia market in the region. With more manufacturers entering the market, the market is anticipated to grow further until 2025,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Europe Frontotemporal Dementia Market By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Country, Forecast & Opportunities, 2025”has evaluated the future growth potential of Europe frontotemporal dementia market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in Europe frontotemporal dementia market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]